Table 3.
Response to treatment in the patient cohort.
| Characteristic | Value (%) | CD5+ | CD5− |
|---|---|---|---|
| Initial Response | |||
| CR | 105 (54.1%) | 60 | 45 |
| PR | 27 (13.9%) | 21 | 6 |
| SD | 12 (6.2%) | 9 | 3 |
| PD | 37 (19.1%) | 25 | 12 |
| Unknown | 13 (0.7%) | 4 | 3 |
| Time of Progression | |||
| None | 65 (33.5%) | 35 | 30 |
| Refractory * | 73 (37.6%) | 58 | 20 |
| Relapse/Progression | 42 (21.6%) | 21 | 16 |
| Unknown | 5 (2.6%) | 3 | 2 |
| Alive at Last Follow-Up | |||
| Alive | 111 (57.2%) | 71 | 40 |
| Deceased | 83 (42.8%) | 51 | 32 |
| Survival Outcomes | |||
| 1-year OS | 154 (76.3%) | 96 | 58 |
| 2-year OS | 137 (66.4%) | 87 | 50 |
| Cause of death | |||
| Lymphoma | 49 (25.3%) | 33 | 16 |
| Treatment related | 17 (8.8%) | 5 | 7 |
| Within 30 days | 12 (6.2%) | 1 | 6 |
| >30 days | 5 (2.6%) | 4 | 1 |
| Other | 4 (2.1%) | 3 | 1 |
| Unknown | 118 (60.8%) | 73 | 45 |
* Defined as partial response or stable disease that did not fully respond to therapy but did not exhibit progression of disease.